Navelbine Oral (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine Oral, is a Vinca alkaloid presented as an oral formulation for oral use. It is used in the treatment of certain cancers, including non‑small cell lung cancer and breast cancer, in adult patients.

GNH USA supplies Navelbine Oral as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is employed in oncology to interfere with cell division in solid tumours. It is indicated for the following conditions: - Non‑small cell lung cancer: improves disease control and prolongs survival when used in combination regimens. - Breast cancer: used as part of combination chemotherapy to reduce tumour burden. - Metastatic solid tumours (selected): provides therapeutic benefit in patients for whom other options are limited.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Neutropenia: reduced white blood cell count. - Anemia: lowered red blood cell levels. - Constipation: decreased bowel movements. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe neutropenia with fever: risk of infection. - Pulmonary toxicity: shortness of breath or cough. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Liver enzyme elevation: potential hepatic injury. - Peripheral neuropathy: tingling or numbness in extremities. - Thrombocytopenia: low platelet count leading to bleeding.

Before initiating therapy with Vinorelbine, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess hepatic function: check liver enzymes prior to each cycle. - Evaluate renal function: adjust use if creatinine clearance is impaired. - Avoid in patients with known hypersensitivity to Vinca alkaloids. - Use effective contraception: prevent pregnancy during treatment. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Vinorelbine can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure. - Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels. - Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression. - Drugs that prolong QT interval: may increase cardiac risk. - Monoclonal antibodies targeting the same pathway: unclear additive effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels. - NSAIDs: can exacerbate gastrointestinal irritation. - Warfarin: potential for altered anticoagulation control. - Antifungal azoles (e.g., fluconazole): may require dose adjustment. - Herbal supplements containing St. John’s wort: possible reduction in efficacy.